BioPhorum Drug Substance’s Post

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this Xtalks webinar, our experts Tiffany M. and Peter Yixiao Zou, Ph.D. will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://lnkd.in/gSQcFr8R #SyneosHealth

An interesting webinar to understand impact of #inflation reduction act on Pharma industry. Do join if you are interested for market acess insight and actionable solutiona from SMEs #IRA #biopharma #lifesciences #marketacess

Join BioPhorum Drug Substance for an exclusive showcase on Post Approval Strategy, Single-Use Systems and Human Performance Optimization Date: 26 September  Time: Session One - 09:00m CET, Session Two - 11:00 EST Location: Online (Register now using the links below) Session One: Register here - https://lnkd.in/dUMUVsmN Session Two: Register here - https://lnkd.in/dUY_9Yyx In today’s fast-paced biopharmaceutical landscape, efficiency and compliance are more critical than ever. This webinar brings together industry experts to provide actionable insights into: - Post Approval Strategy: Navigate regulatory landscapes with confidence - Single-Use Systems: Ensure a resilient supply chain and compliant qualification and application of Single Use Systems across the BioPharmaceutical value chain - Human Performance: Boost operational excellence through workforce optimization For further information about BioPhorum Drug Substance and learn how you can become part of our community visit: https://lnkd.in/ejRyz9te #drugsubstance #postapprovalchange #humanperformance #singleusesystems #connect #collaborate #accelerate

How can you ensure that drugs reach patients through the right channels at the right time? Join us on Thursday, 7th November @ 2pm AEST / 11am SGT to hear from experts from Deloitte as they share insights about the most pressing challenges facing life sciences today, and how enterprise business planning (EBP) can effectively address them. In this webinar, we will: ✅ Explore how the rise of specialty drugs, regulatory challenges, upcoming patent cliffs, new technologies, and a stricter market access environment are reshaping the life sciences landscape. ✅ Share a case study on how a global biopharmaceutical manufacturer used EBP to establish a collaborative demand and capacity planning platform, fostering seamless production planning. ✅ Give you practical guidance - a live demo, actionable steps, and critical considerations. https://lnkd.in/gij2wxad

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, our experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://ow.ly/3E5y30sFbon #SyneosHealth

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, our experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://ow.ly/tcPn30sFxA3 #SyneosHealth

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, #SyneosHealth experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://lnkd.in/gdUqiq8K #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers #ClinicalResearch 

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, our experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://ow.ly/66wY30sFcvk #SyneosHealth

How does the Inflation Reduction Act (IRA) redefine compliance requirements for biopharmaceutical companies? In this XTalks webinar, #SyneosHealth experts Tiffany McCaslin and Peter Zou will explore the IRA regulation changes, the scope of data requirement, and the strategic implications on drug development, pricing and market access. Register here: https://lnkd.in/e-YWkt88 #SyneosHealthLife #WorkHereMattersEverywhere #ClinicalCareers #ClinicalResearch 

A great way to learn about the Inflation Reduction Act.